Literature DB >> 30798533

Influenza-Mediated Lung Infection Models.

Charles E McGee1, Christopher J Sample1, Brita Kilburg-Basnyat2, Kristin A Gabor3, Michael B Fessler3, Kymberly M Gowdy4.   

Abstract

Laboratory rodent influenza infection models have been and continue to be a critical tool for understanding virus-host interactions during infection. The incidence of seasonal influenza infections coupled with the need for novel therapeutics and universal vaccines highlights the need to uncover novel mechanisms of pathogenesis and protection. Mouse models are extremely useful for the evaluation of influenza vaccines and provide an invaluable tool to probe the immune response. This chapter describes the technique of intranasal inoculation of male C57BL/6J mice with an H1N1 strain of influenza (A/Puerto Rico/8/1934) and methods for assessing the optimum dose for infection, viral titers in lung tissue, and severity of disease.

Entities:  

Keywords:  Body weight loss; Focus-forming units; H1N1; Influenza; Intranasal inoculation; Lung damage

Mesh:

Substances:

Year:  2019        PMID: 30798533      PMCID: PMC6675590          DOI: 10.1007/978-1-4939-9167-9_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  23 in total

1.  Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1.

Authors:  Roi Gazit; Raizy Gruda; Moran Elboim; Tal I Arnon; Gil Katz; Hagit Achdout; Jacob Hanna; Udi Qimron; Guy Landau; Evgenia Greenbaum; Zichria Zakay-Rones; Angel Porgador; Ofer Mandelboim
Journal:  Nat Immunol       Date:  2006-03-26       Impact factor: 25.606

2.  Genetically determined resistance to infection by hepatotropic influenza A virus in mice: effect of immunosuppression.

Authors:  O Haller; H Arnheiter; J Lindenmann
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

3.  Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication.

Authors:  M Bergmann; A Garcia-Sastre; E Carnero; H Pehamberger; K Wolff; P Palese; T Muster
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

4.  Protective role of beta interferon in host defense against influenza A virus.

Authors:  Iris Koerner; Georg Kochs; Ulrich Kalinke; Siegfried Weiss; Peter Staeheli
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

Review 5.  Interferon-induced Mx proteins in antiviral host defense.

Authors:  Otto Haller; Peter Staeheli; Georg Kochs
Journal:  Biochimie       Date:  2007-05-08       Impact factor: 4.079

Review 6.  Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.

Authors:  Regina Dutkowski
Journal:  J Antimicrob Chemother       Date:  2010-04       Impact factor: 5.790

7.  Mx1 causes resistance against influenza A viruses in the Mus spretus-derived inbred mouse strain SPRET/Ei.

Authors:  Ineke Vanlaere; Ananza Vanderrijst; Jean-Louis Guénet; Marina De Filette; Claude Libert
Journal:  Cytokine       Date:  2008-03-10       Impact factor: 3.861

Review 8.  Genetic susceptibility and resistance to influenza infection and disease in humans and mice.

Authors:  Rita A Trammell; Linda A Toth
Journal:  Expert Rev Mol Diagn       Date:  2008-07       Impact factor: 5.225

9.  New low-viscosity overlay medium for viral plaque assays.

Authors:  Mikhail Matrosovich; Tatyana Matrosovich; Wolfgang Garten; Hans-Dieter Klenk
Journal:  Virol J       Date:  2006-08-31       Impact factor: 4.099

10.  Host genetic background strongly influences the response to influenza a virus infections.

Authors:  Barkha Srivastava; Paulina Błazejewska; Manuela Hessmann; Dunja Bruder; Robert Geffers; Susanne Mauel; Achim D Gruber; Klaus Schughart
Journal:  PLoS One       Date:  2009-03-18       Impact factor: 3.240

View more
  1 in total

1.  β-Cyclodextrin-containing polymer treatment of cutaneous lupus and influenza improves outcomes.

Authors:  Linsley Kelly; Lyra B Olson; Rachel E Rempel; Jeffrey I Everitt; Dana Levine; Smita K Nair; Mark E Davis; Bruce A Sullenger
Journal:  Mol Ther       Date:  2021-10-08       Impact factor: 11.454

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.